PL3782612T3 - Doustne formulacje analogów cytydyny i sposoby ich zastosowania - Google Patents

Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Info

Publication number: PL3782612T3
Authority: PL; Poland
Prior art keywords: methods; oral formulations; cytidine analogs; cytidine; analogs
Prior art date: 2008-05-15

Application number

PL20201143.3T

Other languages

English (en)

Inventor

Jeffrey B Etter

Mei Lai

Jay T BACKSTROM

Original Assignee

Celgene Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-15

Filing date

2009-05-14

Publication date

2024-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3782612(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-14 Application filed by Celgene Corporation filed Critical Celgene Corporation

2024-03-04 Publication of PL3782612T3 publication Critical patent/PL3782612T3/pl

Links

UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL20201143.3T 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania PL3782612T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US5360908P	2008-05-15	2008-05-15
US20114508P	2008-12-05	2008-12-05
US15787509P	2009-03-05	2009-03-05

Publications (1)

Publication Number	Publication Date
PL3782612T3 true PL3782612T3 (pl)	2024-03-04

Family

ID=40941609

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL13182721T PL2695609T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL09746975T PL2299984T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL20201105.2T PL3782611T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL20201143.3T PL3782612T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL19213148T PL3692983T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL13182721T PL2695609T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL09746975T PL2299984T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL20201105.2T PL3782611T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL19213148T PL3692983T3 (pl)	2008-05-15	2009-05-14	Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Country Status (34)

Country	Link
US (11)	US8846628B2 (pl)
EP (6)	EP2695609B1 (pl)
JP (3)	JP2011520880A (pl)
KR (1)	KR101633134B1 (pl)
CN (3)	CN103479586B (pl)
AR (1)	AR071808A1 (pl)
AU (3)	AU2009246926B2 (pl)
BR (1)	BRPI0912717A2 (pl)
CA (3)	CA2761582C (pl)
CL (2)	CL2009001170A1 (pl)
CO (1)	CO6300930A2 (pl)
CR (1)	CR11789A (pl)
CY (3)	CY1121350T1 (pl)
DK (5)	DK3782611T3 (pl)
EC (1)	ECSP10010665A (pl)
ES (5)	ES2969144T3 (pl)
FI (1)	FI3782612T3 (pl)
HR (5)	HRP20231439T1 (pl)
HU (5)	HUE064677T2 (pl)
IL (2)	IL238087B (pl)
LT (5)	LT3782612T (pl)
MX (2)	MX2010012470A (pl)
MY (1)	MY161593A (pl)
NI (1)	NI201000193A (pl)
NZ (3)	NZ589437A (pl)
PE (2)	PE20091971A1 (pl)
PL (5)	PL2695609T3 (pl)
PT (5)	PT3692983T (pl)
RU (3)	RU2476207C2 (pl)
SG (1)	SG193206A1 (pl)
SI (5)	SI2695609T1 (pl)
TW (3)	TWI618538B (pl)
WO (1)	WO2009139888A1 (pl)
ZA (1)	ZA201008229B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8404716B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en)	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US8497292B2 (en)	2005-12-28	2013-07-30	Translational Therapeutics, Inc.	Translational dysfunction based therapeutics
CA2742252A1 (en) *	2007-11-01	2009-05-07	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
HUE064677T2 (hu)	2008-05-15	2024-04-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására
US20150290228A1 (en) *	2008-05-15	2015-10-15	Jay T. BACKSTROM	Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) *	2009-02-10	2010-08-19	Celgene International Sarl	Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) *	2009-12-02	2013-07-23	Nimble Epitech, Llc	Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US8759303B2 (en)	2010-06-07	2014-06-24	Telik, Inc.	Compositions and methods for treating myelodysplastic syndrome
US20140155344A1 (en) *	2010-06-07	2014-06-05	Neil P. Desai	Combination therapy methods for treating proliferative diseases
US20110301102A1 (en) *	2010-06-07	2011-12-08	Telik, Inc.	Compositions and methods for treating myelodysplastic syndrome
WO2012106299A1 (en) *	2011-01-31	2012-08-09	Celgene Corporation	Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) *	2011-02-01	2012-08-01	Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano	Markers of cutaneous melanoma and uses thereof
MX2013010945A (es)	2011-03-31	2014-03-12	Celgene Internat Sarl	Sintesis de 5 - azacitidina.
EA201490911A1 (ru) *	2011-11-01	2014-09-30	Селджин Корпорейшн	Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
JP6231988B2 (ja)	2011-11-03	2017-11-15	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
MX2015000804A (es) *	2012-07-20	2016-03-11	Star Biotechnology Llc	Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
KR20240010105A (ko)	2014-03-14	2024-01-23	아지오스 파마슈티컬스 아이엔씨.	치료적으로 활성인 화합물의 약제학적 조성물
WO2015195634A1 (en)	2014-06-17	2015-12-23	Celgne Corporation	Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3925609A1 (en)	2014-08-22	2021-12-22	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
AU2016340098B2 (en) *	2015-10-15	2022-06-02	Celgene Corporation	Combination therapy for treating malignancies
BR112018007656A2 (pt) *	2015-10-15	2018-11-06	Agios Pharmaceuticals Inc	terapia de combinação para tratamento de doenças malignas
MX2018004587A (es)	2015-10-15	2018-08-14	Agios Pharmaceuticals Inc	Terapia de combinacion para tratar tumores malignos.
EP3960182A1 (en)	2015-12-03	2022-03-02	Epidestiny, Inc.	Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
US11035850B2 (en)	2016-04-12	2021-06-15	The Johns Hopkins University	Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
EA039874B1 (ru) *	2019-06-06	2022-03-22	Общество С Ограниченной Ответственностью "Технология Лекарств"	Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
KR20220050874A (ko) *	2019-06-20	2022-04-25	셀젠 콴티셀 리서치, 인크.	백혈병 또는 골수이형성 증후군을 치료하기 위한 베네토클락스, 길테리티닙, 미도스타우린 또는 다른 화합물과 조합된 아자시티딘
BR112022007376A2 (pt)	2019-10-21	2022-07-05	Novartis Ag	Terapias de combinação com venetoclax e inibidores de tim-3
MX2022004769A (es)	2019-10-21	2022-05-16	Novartis Ag	Inhibidores de tim-3 y sus usos.
TW202135858A (zh)	2019-12-20	2021-10-01	瑞士商諾華公司	抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
WO2021144657A1 (en)	2020-01-17	2021-07-22	Novartis Ag	Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115989229A (zh)	2020-07-23	2023-04-18	南方研究院	5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
EP4262812A1 (en) *	2020-12-18	2023-10-25	Southern Research Institute	6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en)	2021-03-12	2022-09-15	Celgene Corporation	Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
AU2022370354A1 (en)	2021-10-19	2024-05-30	Akirabio, Inc.	Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2913408A (en)	1956-12-28	1959-11-17	Dow Chemical Co	Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (pl) *	1963-12-22
CH527207A (de)	1968-05-08	1972-08-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de)	1968-11-12	1971-05-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) *	1970-03-14	1981-04-02	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en)	1971-01-26	1972-09-15	Ceskoslovenska Akademie Ved	Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) *	1971-05-04	1982-06-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) *	1975-02-24	1976-09-02	Schering Ag	Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) *	1977-12-20	1979-06-21	Schering Ag	Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja)	1983-03-30	1984-10-11	日産自動車株式会社	トラツクのリヤボデイ構造
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
ATE126510T1 (de)	1989-05-10	1995-09-15	Hoffmann La Roche	Herstellung von isochinolinderivaten.
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US6432924B1 (en) *	1993-12-26	2002-08-13	East Carolina University	Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) *	1994-06-21	1994-08-10	Danbiosyst Uk	Colonic drug delivery composition
US5700640A (en) *	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en)	1994-10-17	1996-07-23	Trojan Technologies Inc.	Method of cleaning fouling materials from a radiation module
BR9712527A (pt) *	1996-10-16	2000-03-08	Icn Pharmaceuticals	L-nucleosìdeos monocìclicos, análogos e seus empregos
EP0998271B3 (en)	1997-06-06	2014-10-29	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en)	1997-06-06	2003-10-21	Depomed, Inc.	Extending the duration of drug release within the stomach during the fed mode
US6566395B1 (en)	1999-05-25	2003-05-20	Biomedicines, Inc.	Methods of treating proliferative disorders
US6803195B1 (en)	1999-07-02	2004-10-12	Ramot At Tel-Aviv University Ltd.	Facile detection of cancer and cancer risk based on level of coordination between alleles
WO2001005406A1 (fr) *	1999-07-16	2001-01-25	Amato Pharmaceutical Products, Ltd.	Preparations de glycyrrhizine pour absorption par voie transmuqueuse
CA2396782A1 (en)	2000-02-04	2001-08-09	Depomed, Inc.	Shell-and-core dosage form approaching zero-order drug release
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
EP1399159A4 (en)	2001-06-01	2007-02-14	Cytovia Inc	4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) *	2002-03-29	2003-11-27	Texas Tech University System	Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
EP1545558A4 (en) *	2002-09-24	2010-02-17	Koronis Pharmaceuticals Inc	1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003286836A1 (en)	2002-10-31	2004-06-07	Supergen, Inc.	Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004058253A1 (en)	2002-12-18	2004-07-15	Cytovia, Inc.	3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US7038038B2 (en)	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6943249B2 (en) *	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
EP1667680A4 (en) *	2003-08-29	2008-10-08	Aton Pharma Inc	COMBINED METHODS OF TREATING CANCER
US7192781B2 (en) *	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) *	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
US20060063735A1 (en)	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
CN100374160C (zh) *	2004-11-22	2008-03-12	山东蓝金生物工程有限公司	一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) *	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
PL3248600T3 (pl)	2005-02-18	2020-09-07	Abraxis Bioscience, Llc	Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
DK1868579T3 (da)	2005-03-07	2011-01-10	Bayer Schering Pharma Ag	Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
CN100500212C (zh) *	2005-04-06	2009-06-17	山东蓝金生物工程有限公司	一种抗实体肿瘤药物组合物
US8058260B2 (en) *	2006-05-22	2011-11-15	Xenoport, Inc.	2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) *	2006-09-01	2008-03-06	Pharmion Corporation	Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en)	2007-01-11	2008-07-24	Ivax Pharmaceuticals S.R.O.	Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en)	2007-01-25	2009-11-11	Nevada Cancer Institute	Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja)	2007-07-25	2013-04-03	キヤノン株式会社	プリント配線板およびそれを用いた電子機器
WO2009016617A2 (en)	2007-08-02	2009-02-05	Chemagis Ltd.	Stable highly pure azacitidine and preparation methods therefor
MX2010003002A (es)	2007-09-26	2010-07-05	Sinai School Medicine	Analogos de azacitidina y sus usos.
EP2048151A1 (en) *	2007-10-10	2009-04-15	Cilag AG	Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
CA2742252A1 (en) *	2007-11-01	2009-05-07	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
HUE064677T2 (hu) *	2008-05-15	2024-04-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására
EP2321302B1 (en) *	2008-08-01	2014-10-29	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
EP2520581A1 (en) *	2008-08-06	2012-11-07	Sicor, Inc.	Method for the determination the purity of 5-Azacytidine
CN102216315B (zh) *	2008-08-08	2016-06-29	台湾神隆股份有限公司	制备5-氮杂胞嘧啶核苷和其衍生物的方法
EP2752189B1 (en)	2008-11-22	2016-10-26	F. Hoffmann-La Roche AG	Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
US20110042247A1 (en) *	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
WO2011014541A1 (en)	2009-07-30	2011-02-03	Eagle Pharmaceuticals, Inc.	Stable formulations of azacitidine
IT1399195B1 (it) *	2010-03-30	2013-04-11	Chemi Spa	Processo per la sintesi di azacitidina e decitabina
WO2012106299A1 (en) *	2011-01-31	2012-08-09	Celgene Corporation	Pharmaceutical compositions of cytidine analogs and methods of use thereof
MX2013010945A (es)	2011-03-31	2014-03-12	Celgene Internat Sarl	Sintesis de 5 - azacitidina.
WO2013022872A1 (en)	2011-08-10	2013-02-14	Celgene Corporation	Gene methylation biomarkers and methods of use thereof
EA201490911A1 (ru) *	2011-11-01	2014-09-30	Селджин Корпорейшн	Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина

2009
- 2009-05-14 HU HUE20201143A patent/HUE064677T2/hu unknown
- 2009-05-14 ES ES20201143T patent/ES2969144T3/es active Active
- 2009-05-14 CN CN201310363158.0A patent/CN103479586B/zh not_active Ceased
- 2009-05-14 EP EP13182721.4A patent/EP2695609B1/en active Active
- 2009-05-14 NZ NZ589437A patent/NZ589437A/xx unknown
- 2009-05-14 LT LTEP20201143.3T patent/LT3782612T/lt unknown
- 2009-05-14 HR HRP20231439TT patent/HRP20231439T1/hr unknown
- 2009-05-14 NZ NZ623495A patent/NZ623495A/en unknown
- 2009-05-14 NZ NZ602833A patent/NZ602833A/en unknown
- 2009-05-14 CL CL2009001170A patent/CL2009001170A1/es unknown
- 2009-05-14 HU HUE09746975A patent/HUE042825T2/hu unknown
- 2009-05-14 PL PL13182721T patent/PL2695609T3/pl unknown
- 2009-05-14 SI SI200932020T patent/SI2695609T1/sl unknown
- 2009-05-14 HU HUE20201105A patent/HUE059635T2/hu unknown
- 2009-05-14 FI FIEP20201143.3T patent/FI3782612T3/fi active
- 2009-05-14 CA CA2761582A patent/CA2761582C/en active Active
- 2009-05-14 PL PL09746975T patent/PL2299984T3/pl unknown
- 2009-05-14 MY MYPI2010005331A patent/MY161593A/en unknown
- 2009-05-14 US US12/466,213 patent/US8846628B2/en active Active
- 2009-05-14 LT LTEP13182721.4T patent/LT2695609T/lt unknown
- 2009-05-14 PT PT192131480T patent/PT3692983T/pt unknown
- 2009-05-14 PT PT202011052T patent/PT3782611T/pt unknown
- 2009-05-14 PT PT202011433T patent/PT3782612T/pt unknown
- 2009-05-14 SI SI200931918T patent/SI2299984T1/sl unknown
- 2009-05-14 LT LTEP19213148.0T patent/LT3692983T/lt unknown
- 2009-05-14 ES ES19213148T patent/ES2893785T3/es active Active
- 2009-05-14 EP EP20201143.3A patent/EP3782612B1/en active Active
- 2009-05-14 BR BRPI0912717-8A2A patent/BRPI0912717A2/pt not_active Application Discontinuation
- 2009-05-14 SI SI200932188T patent/SI3782612T1/sl unknown
- 2009-05-14 EP EP19213148.0A patent/EP3692983B1/en active Active
- 2009-05-14 CA CA3094590A patent/CA3094590A1/en not_active Abandoned
- 2009-05-14 ES ES13182721T patent/ES2774226T3/es active Active
- 2009-05-14 DK DK20201105.2T patent/DK3782611T3/da active
- 2009-05-14 CA CA3094580A patent/CA3094580C/en active Active
- 2009-05-14 EP EP20201105.2A patent/EP3782611B1/en active Active
- 2009-05-14 LT LTEP20201105.2T patent/LT3782611T/lt unknown
- 2009-05-14 KR KR1020107028070A patent/KR101633134B1/ko active IP Right Grant
- 2009-05-14 RU RU2010151428/15A patent/RU2476207C2/ru active
- 2009-05-14 MX MX2010012470A patent/MX2010012470A/es active IP Right Grant
- 2009-05-14 PT PT09746975T patent/PT2299984T/pt unknown
- 2009-05-14 SI SI200932170T patent/SI3782611T1/sl unknown
- 2009-05-14 MX MX2014010978A patent/MX363023B/es unknown
- 2009-05-14 HR HRP20221064TT patent/HRP20221064T1/hr unknown
- 2009-05-14 AU AU2009246926A patent/AU2009246926B2/en active Active
- 2009-05-14 SI SI200932143T patent/SI3692983T1/sl unknown
- 2009-05-14 DK DK20201143.3T patent/DK3782612T3/da active
- 2009-05-14 EP EP09746975.3A patent/EP2299984B1/en active Active
- 2009-05-14 PL PL20201105.2T patent/PL3782611T3/pl unknown
- 2009-05-14 PL PL20201143.3T patent/PL3782612T3/pl unknown
- 2009-05-14 LT LTEP09746975.3T patent/LT2299984T/lt unknown
- 2009-05-14 DK DK13182721.4T patent/DK2695609T3/da active
- 2009-05-14 HU HUE19213148A patent/HUE055911T2/hu unknown
- 2009-05-14 ES ES20201105T patent/ES2927556T3/es active Active
- 2009-05-14 CN CN201510982946.7A patent/CN105535008A/zh active Pending
- 2009-05-14 CN CN200980127929.8A patent/CN102099018B/zh not_active Ceased
- 2009-05-14 DK DK09746975.3T patent/DK2299984T3/en active
- 2009-05-14 SG SG2013061601A patent/SG193206A1/en unknown
- 2009-05-14 ES ES09746975T patent/ES2712506T3/es active Active
- 2009-05-14 HU HUE13182721A patent/HUE047707T2/hu unknown
- 2009-05-14 DK DK19213148.0T patent/DK3692983T3/da active
- 2009-05-14 JP JP2011509487A patent/JP2011520880A/ja not_active Withdrawn
- 2009-05-14 PL PL19213148T patent/PL3692983T3/pl unknown
- 2009-05-14 WO PCT/US2009/002999 patent/WO2009139888A1/en active Application Filing
- 2009-05-14 PT PT131827214T patent/PT2695609T/pt unknown
- 2009-05-14 EP EP23207760.2A patent/EP4327888A3/en active Pending
- 2009-05-15 AR ARP090101759A patent/AR071808A1/es not_active Application Discontinuation
- 2009-05-15 TW TW105141639A patent/TWI618538B/zh active
- 2009-05-15 PE PE2009000685A patent/PE20091971A1/es not_active Application Discontinuation
- 2009-05-15 PE PE2014002005A patent/PE20142440A1/es not_active Application Discontinuation
- 2009-05-15 TW TW098116326A patent/TWI522103B/zh active
- 2009-05-15 TW TW104100098A patent/TW201513869A/zh unknown
2010
- 2010-11-12 NI NI201000193A patent/NI201000193A/es unknown
- 2010-11-12 CR CR11789A patent/CR11789A/es unknown
- 2010-11-14 IL IL238087A patent/IL238087B/en active IP Right Grant
- 2010-11-14 IL IL209307A patent/IL209307A/en active IP Right Grant
- 2010-11-17 ZA ZA2010/08229A patent/ZA201008229B/en unknown
- 2010-12-07 EC EC2010010665A patent/ECSP10010665A/es unknown
- 2010-12-15 CO CO10157384A patent/CO6300930A2/es not_active Application Discontinuation
2012
- 2012-11-09 RU RU2012147739/15A patent/RU2012147739A/ru unknown
2013
- 2013-04-05 AU AU2013202665A patent/AU2013202665B2/en active Active
- 2013-04-22 CL CL2013001097A patent/CL2013001097A1/es unknown
2014
- 2014-08-19 US US14/463,424 patent/US20150056280A1/en not_active Abandoned
- 2014-12-12 JP JP2014251911A patent/JP6105547B2/ja active Active
2015
- 2015-05-27 AU AU2015202884A patent/AU2015202884B2/en active Active
- 2015-06-30 US US14/788,606 patent/US20150374732A1/en not_active Abandoned
2017
- 2017-03-02 JP JP2017039320A patent/JP6426778B2/ja active Active
- 2017-12-07 US US15/835,088 patent/US10220050B2/en active Active
2018
- 2018-03-15 RU RU2018109222A patent/RU2765076C2/ru active
2019
- 2019-01-09 US US16/244,014 patent/US10463683B2/en active Active
- 2019-01-16 HR HRP20190100TT patent/HRP20190100T1/hr unknown
- 2019-02-25 CY CY20191100231T patent/CY1121350T1/el unknown
- 2019-09-25 US US16/582,779 patent/US10646503B2/en active Active
2020
- 2020-01-21 HR HRP20200096TT patent/HRP20200096T1/hr unknown
- 2020-02-24 CY CY20201100168T patent/CY1122681T1/el unknown
- 2020-03-27 US US16/833,410 patent/US20200316099A1/en not_active Abandoned
2021
- 2021-09-02 HR HRP20211398TT patent/HRP20211398T1/hr unknown
- 2021-10-20 CY CY20211100917T patent/CY1124720T1/el unknown
- 2021-11-22 US US17/533,033 patent/US11571436B2/en active Active
- 2021-12-16 US US17/553,456 patent/US20220105118A1/en not_active Abandoned
2022
- 2022-11-10 US US17/984,939 patent/US20230241086A1/en active Pending
2023
- 2023-04-24 US US18/138,473 patent/US20230255996A1/en active Pending

Also Published As

Publication number	Publication date
PT3782612T (pt)	2024-01-18
NZ602833A (en)	2014-04-30
EP3782611A1 (en)	2021-02-24
MY161593A (en)	2017-04-28
CR11789A (es)	2011-02-21
CY1124720T1 (el)	2022-07-22
CL2013001097A1 (es)	2013-11-29
ES2927556T3 (es)	2022-11-08
CY1122681T1 (el)	2020-10-14
HUE059635T2 (hu)	2022-12-28
EP4327888A2 (en)	2024-02-28
PL2695609T3 (pl)	2020-05-18
CN103479586B (zh)	2017-03-01
US20200101095A1 (en)	2020-04-02
PL3692983T3 (pl)	2021-12-27
IL209307A0 (en)	2011-01-31
ZA201008229B (en)	2012-02-29
RU2765076C2 (ru)	2022-01-25
US10646503B2 (en)	2020-05-12
JP6105547B2 (ja)	2017-03-29
EP3692983A1 (en)	2020-08-12
TW201006478A (en)	2010-02-16
CN103479586A (zh)	2014-01-01
HUE055911T2 (hu)	2021-12-28
ES2774226T3 (es)	2020-07-17
US20090286752A1 (en)	2009-11-19
NZ623495A (en)	2015-08-28
PT3692983T (pt)	2021-11-08
ECSP10010665A (es)	2011-01-31
PL2299984T3 (pl)	2019-07-31
PE20142440A1 (es)	2015-01-28
HUE064677T2 (hu)	2024-04-28
HUE047707T2 (hu)	2020-05-28
SG193206A1 (en)	2013-09-30
BRPI0912717A2 (pt)	2014-12-23
US20220079964A1 (en)	2022-03-17
MX363023B (es)	2019-03-05
AU2015202884B2 (en)	2017-02-23
US10220050B2 (en)	2019-03-05
EP2299984A1 (en)	2011-03-30
JP2011520880A (ja)	2011-07-21
WO2009139888A1 (en)	2009-11-19
TWI618538B (zh)	2018-03-21
US20230255996A1 (en)	2023-08-17
CA2761582A1 (en)	2009-11-19
ES2969144T3 (es)	2024-05-16
FI3782612T3 (fi)	2024-01-16
SI3692983T1 (sl)	2021-11-30
LT2299984T (lt)	2019-03-25
SI2695609T1 (sl)	2020-03-31
RU2012147739A (ru)	2014-05-20
CY1121350T1 (el)	2020-05-29
EP2695609A1 (en)	2014-02-12
CA2761582C (en)	2022-06-07
US20180153916A1 (en)	2018-06-07
TW201729817A (zh)	2017-09-01
LT3782612T (lt)	2023-12-27
RU2018109222A3 (pl)	2021-07-02
EP3782612B1 (en)	2023-11-08
SI2299984T1 (sl)	2019-04-30
US20200316099A1 (en)	2020-10-08
EP3692983B1 (en)	2021-08-11
IL209307A (en)	2016-02-29
CA3094580A1 (en)	2009-11-19
NZ589437A (en)	2012-11-30
SI3782611T1 (sl)	2022-10-28
US20230241086A1 (en)	2023-08-03
RU2476207C2 (ru)	2013-02-27
NI201000193A (es)	2011-08-01
PE20091971A1 (es)	2010-01-15
CO6300930A2 (es)	2011-07-21
US10463683B2 (en)	2019-11-05
AU2009246926A1 (en)	2009-11-19
JP2015110575A (ja)	2015-06-18
EP2299984B1 (en)	2018-11-28
EP4327888A3 (en)	2024-05-22
KR101633134B1 (ko)	2016-06-23
LT3692983T (lt)	2021-11-10
US20190231803A1 (en)	2019-08-01
US20220105118A1 (en)	2022-04-07
EP2695609B1 (en)	2019-12-11
CN102099018A (zh)	2011-06-15
TW201513869A (zh)	2015-04-16
RU2010151428A (ru)	2012-06-20
DK3782612T3 (da)	2024-01-15
JP2017137326A (ja)	2017-08-10
PT2695609T (pt)	2020-03-02
AU2015202884A1 (en)	2015-06-18
TWI522103B (zh)	2016-02-21
SI3782612T1 (sl)	2024-02-29
AU2009246926B2 (en)	2014-06-26
PT2299984T (pt)	2019-02-25
PT3782611T (pt)	2022-11-18
HRP20211398T1 (hr)	2021-12-10
US20150056280A1 (en)	2015-02-26
MX2010012470A (es)	2010-12-02
AU2013202665A1 (en)	2013-05-02
HRP20221064T1 (hr)	2022-11-11
EP3782612A1 (en)	2021-02-24
ES2712506T3 (es)	2019-05-13
HUE042825T2 (hu)	2019-07-29
CL2009001170A1 (es)	2010-06-04
AR071808A1 (es)	2010-07-14
HRP20200096T1 (hr)	2020-04-03
US20150374732A1 (en)	2015-12-31
CA3094580C (en)	2021-05-18
CA3094590A1 (en)	2009-11-19
HRP20231439T1 (hr)	2024-03-01
CN102099018B (zh)	2016-01-13
HRP20190100T1 (hr)	2019-04-05
EP3782611B1 (en)	2022-07-06
US11571436B2 (en)	2023-02-07
PL3782611T3 (pl)	2022-11-07
JP6426778B2 (ja)	2018-11-21
DK3692983T3 (da)	2021-09-20
RU2018109222A (ru)	2019-09-17
LT2695609T (lt)	2020-02-10
DK3782611T3 (da)	2022-09-05
LT3782611T (lt)	2022-10-10
IL238087B (en)	2019-01-31
DK2299984T3 (en)	2019-03-04
DK2695609T3 (da)	2020-02-10
ES2893785T3 (es)	2022-02-10
AU2013202665B2 (en)	2015-06-25
KR20110015629A (ko)	2011-02-16
US8846628B2 (en)	2014-09-30
CN105535008A (zh)	2016-05-04

Publication	Publication Date	Title
HRP20190100T1 (hr)	2019-04-05	Oralne formulacije analoga citidina i postupci za njihovu upotrebu
EP2448406A4 (en)	2013-06-26	ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
GB0915693D0 (en)	2009-10-07	Fatty acid formulations and methods of use thereof
PT2173345E (pt)	2015-11-19	Formulação oral de metadoxina
EP2001400A4 (en)	2013-01-23	ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
ZA200905741B (en)	2010-06-30	Indenoisoquinolinone analogs and methods of use thereof
EP2170404A4 (en)	2011-01-19	COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
PL2285450T3 (pl)	2019-03-29	Kompozycje do higieny jamy ustnej i sposoby
EP2310009A4 (en)	2011-10-19	PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES
EP2367421A4 (en)	2013-03-13	ORAL FORMULAS
ZA201100944B (en)	2012-07-25	Oral formulations of chemotherapeutic agents
EP2274325A4 (en)	2011-05-25	ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
IL210956A0 (en)	2011-04-28	Methionine analogs and methods of using same
TWM388323U (en)	2010-09-11	Improved structure of dental handpiece (1)